EHA 2021 | T-ALL diagnosis: cytogenetics, genomics and risk assessment
Anthony Moorman, PhD, Newcastle University, Newcastle, UK, talks on the diagnosis of T-cell acute lymphoblastic leukemia (T-ALL), highlighting the challenges of identifying risk factors due to a small patient population and a high proportion of independent abnormalities. Prof. Moorman gives an overview of key aspects of genetic analysis, commenting on the consideration of ABL-class fusions in tyrosine kinase inhibitor use, the high risk of relapse in patients with KMT22a rearrangements, and the importance of identifying key genetic lesions in T-ALL. Prof. Moorman also talks on the limitations of a risk stratification model using the mutational status of NOTCH1, FBXO7, KRAS, NRAS and PTEN genes. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
